The FDA granted accelerated approval for Sanofi’s Tzield (teplizumab-mzwv) for patients aged 8 to 17. This indication targets children and adolescents recently diagnosed with stage 3 type 1 diabetes (T1D).
Tzield is the first disease-modifying therapy available for this patient population. The treatment shifts clinical focus from insulin-based symptom management to addressing the underlying autoimmune attack.
Data from the Phase 3 PROTECT study showed Tzield significantly slowed the decline of natural insulin production compared to a placebo. The therapy preserves insulin-producing beta cells to delay disease progression. This decision expands Tzield’s previous approval for delaying stage 3 onset in at-risk stage 2 patients.